JP4709465B2 - アルギニンデイミナーゼの新規突然変異体 - Google Patents

アルギニンデイミナーゼの新規突然変異体 Download PDF

Info

Publication number
JP4709465B2
JP4709465B2 JP2001580381A JP2001580381A JP4709465B2 JP 4709465 B2 JP4709465 B2 JP 4709465B2 JP 2001580381 A JP2001580381 A JP 2001580381A JP 2001580381 A JP2001580381 A JP 2001580381A JP 4709465 B2 JP4709465 B2 JP 4709465B2
Authority
JP
Japan
Prior art keywords
arginine deiminase
arginine
modified
amino acid
enzyme
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP2001580381A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003533186A5 (enExample
JP2003533186A (ja
Inventor
エンサー，チヤールズ・マーク
ホルツバーグ，フレデリク・ウエイン
クラーク，マイク・エイ
Original Assignee
ポラリス・グループ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ポラリス・グループ filed Critical ポラリス・グループ
Publication of JP2003533186A publication Critical patent/JP2003533186A/ja
Publication of JP2003533186A5 publication Critical patent/JP2003533186A5/ja
Application granted granted Critical
Publication of JP4709465B2 publication Critical patent/JP4709465B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/03—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in linear amidines (3.5.3)
    • C12Y305/03006—Arginine deiminase (3.5.3.6)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
  • Dairy Products (AREA)
JP2001580381A 2000-05-04 2001-05-02 アルギニンデイミナーゼの新規突然変異体 Expired - Lifetime JP4709465B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/564,559 US6635462B1 (en) 1997-05-12 2000-05-04 Mutated form of arginine deiminase
US09/564,559 2000-05-04
PCT/US2001/014116 WO2001083774A2 (en) 2000-05-04 2001-05-02 Novel mutated form of arginine deiminase

Publications (3)

Publication Number Publication Date
JP2003533186A JP2003533186A (ja) 2003-11-11
JP2003533186A5 JP2003533186A5 (enExample) 2008-07-17
JP4709465B2 true JP4709465B2 (ja) 2011-06-22

Family

ID=24254954

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001580381A Expired - Lifetime JP4709465B2 (ja) 2000-05-04 2001-05-02 アルギニンデイミナーゼの新規突然変異体

Country Status (11)

Country Link
US (2) US6635462B1 (enExample)
EP (1) EP1278868B9 (enExample)
JP (1) JP4709465B2 (enExample)
AT (1) ATE382697T1 (enExample)
AU (1) AU2001259353A1 (enExample)
CY (1) CY1107351T1 (enExample)
DE (1) DE60132190T2 (enExample)
DK (1) DK1278868T3 (enExample)
ES (1) ES2296750T3 (enExample)
PT (1) PT1278868E (enExample)
WO (1) WO2001083774A2 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8143210B2 (en) 2002-02-14 2012-03-27 The Board Of Trustees Of The Leland Stanford Junior University Enzyme treatment of foodstuffs for celiac sprue
AU2003215272B2 (en) * 2002-02-14 2008-04-03 The Board Of Trustees Of The Leland Stanford Junior University Enzyme treatment of foodstuffs for celiac sprue
ES2477118T3 (es) * 2002-11-18 2014-07-15 Polaris Group Método para inhibir la replicaci�n viral in vivo
ATE554392T1 (de) 2002-11-20 2012-05-15 Univ Leland Stanford Junior Diagnoseverfahren für sprue/zöliakie
US7579313B2 (en) * 2003-11-18 2009-08-25 The Board Of Trustees Of The Leland Stanford Junior University Transglutaminase inhibitors and methods of use thereof
CN101002945B (zh) * 2006-01-20 2012-09-05 清华大学 一种用于肿瘤治疗的新型复合物
EP2136833B1 (en) * 2007-03-16 2019-05-01 The Board of Trustees of the Leland Stanford Junior University Combination enzyme therapy for digestion of dietary gluten
US8148105B2 (en) * 2007-03-16 2012-04-03 The Board Of Trustees Of The Leland Stanford Junior University Scaleable manufacturing process for cysteine endoprotease B, isoform 2
EP2295560A1 (en) 2009-09-14 2011-03-16 RWTH Aachen University Directed evolution of arginine deiminase for increased activity at physiological pH
US10118754B2 (en) * 2011-11-22 2018-11-06 Kimberly-Clark Worldwide, Inc. Method of folding pant-like disposable absorbent garments in a chute
US11123230B2 (en) * 2011-11-22 2021-09-21 Kimberly-Clark Worldwide, Inc. Method of folding pant-like disposable absorbent garments in a chute
US9918881B2 (en) 2011-11-22 2018-03-20 Kimberly-Clark Worldwide, Inc. Method of folding pant-like disposable absorbent garments in a trough
JP2014521602A (ja) * 2012-04-04 2014-08-28 ポラリス グループ アルギニンデイミナーゼを用いる処置方法
WO2014151982A2 (en) 2013-03-15 2014-09-25 Polaris Group Arginine deiminase with reduced cross-reactivity toward adi – peg 20 antibodies for cancer treatment
TWI676683B (zh) * 2014-03-14 2019-11-11 開曼群島商瑞華藥業集團 用於癌症治療之對ａｄｉ－ｐｅｇ２０抗體交叉反應性降低之精胺酸去亞胺酶
WO2015143006A1 (en) * 2014-03-18 2015-09-24 Tdw Group Engineered chimeric pegylated adi and methods of use
CA2961602A1 (en) 2014-09-16 2016-03-24 Polaris Group Arginine deiminase with reduced cross-reactivity toward adi - peg 20 antibodies for cancer treatment
CN104726478A (zh) * 2015-03-09 2015-06-24 武汉远大弘元股份有限公司 表达精氨酸脱亚胺酶基因的重组大肠杆菌及其应用
US10435682B2 (en) 2016-02-19 2019-10-08 University Of South Florida Arginine deiminase gene therapy for disordered proteins
US12281339B2 (en) 2016-07-05 2025-04-22 Polaris Group Combination cancer immunotherapies with arginine depletion agents
EP3534963B1 (en) 2016-11-02 2024-04-17 Polaris Group Formulations of pegylated arginine deiminase
CN108265044B (zh) * 2016-12-31 2021-05-11 江苏众红生物工程创药研究院有限公司 聚乙二醇定点修饰的精氨酸脱亚胺酶及其制备方法与应用
CN112442496B (zh) * 2019-08-28 2023-05-12 江苏众红生物工程创药研究院有限公司 精氨酸脱亚胺酶突变体及其应用
CN118792288B (zh) * 2024-06-19 2025-03-04 中国医科大学附属第四医院 一种pH稳定性高的精氨酸脱亚胺酶突变体及其在肿瘤治疗中的应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4800159A (en) 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
JP2900279B2 (ja) 1989-08-02 1999-06-02 株式会社ジャパンエナジー 新規なアルギニンデイミナーゼ、その製造法及び該酵素を有効成分とする制癌剤
JP2736145B2 (ja) 1990-01-11 1998-04-02 関東電化工業株式会社 パーハロゲン化エチレンの製造法
JP3209338B2 (ja) 1990-09-10 2001-09-17 株式会社ジャパンエナジー ポリエチレングリコール修飾アルギニンデイミナーゼおよびその製造法
US5372942A (en) 1992-02-10 1994-12-13 Coriell Institute For Medical Research Protease K resistant arginine deiminase, its method of preparation and its use as an anti-neoplastic agent
US5804183A (en) 1997-01-31 1998-09-08 Enzon, Inc. Arginine deminase derived from mycoplasma arthritidis and polymer conjugates containing the same
AU740207B2 (en) * 1997-02-06 2001-11-01 Novozymes A/S Polypeptide-polymer conjugates having added and/or removed attachment groups
US6183738B1 (en) 1997-05-12 2001-02-06 Phoenix Pharamacologics, Inc. Modified arginine deiminase
US6180387B1 (en) 1997-08-11 2001-01-30 Smithkline Beecham Corporation Arginine deiminase

Also Published As

Publication number Publication date
US20040258675A1 (en) 2004-12-23
DE60132190T2 (de) 2008-12-11
WO2001083774A3 (en) 2002-05-23
JP2003533186A (ja) 2003-11-11
US6635462B1 (en) 2003-10-21
EP1278868A2 (en) 2003-01-29
DK1278868T3 (da) 2008-05-19
EP1278868B9 (en) 2008-10-29
WO2001083774A2 (en) 2001-11-08
PT1278868E (pt) 2008-04-11
AU2001259353A1 (en) 2001-11-12
EP1278868B1 (en) 2008-01-02
CY1107351T1 (el) 2012-12-19
DE60132190D1 (de) 2008-02-14
ES2296750T3 (es) 2008-05-01
ATE382697T1 (de) 2008-01-15

Similar Documents

Publication Publication Date Title
US6635462B1 (en) Mutated form of arginine deiminase
Tan et al. Polyethylene glycol conjugation of recombinant methioninase for cancer therapy
CN1169951C (zh) 被修饰的精氨酸脱亚胺酶
KR102076364B1 (ko) 사람 아르기나제 및 페길화된 사람 아르기나제 및 그의 용도
CN101812438B (zh) 一种精氨酸脱亚氨酶突变体及其制备与应用
US11021690B2 (en) Mutant-type uricase, PEG modified mutant-type uricase, and application thereof
US8663967B2 (en) Arginine deiminase mutant and preparation and application thereof
JP7729842B2 (ja) ｒｈＦＧＦ２１融合タンパク質、ｒｈＦＧＦ２１融合タンパク質をコードするポリヌクレオチド、ｒｈＦＧＦ２１融合タンパク質を含有する組成物、及びｒｈＦＧＦ２１融合タンパク質の使用
MXPA02007545A (es) Urato oxidasa libre de agregados, para preparacion de conjugado de polimero no-inmunogenicos.
CN1322141A (zh) 聚乙二醇或聚环氧乙烷－尿酸氧化酶结合物及其应用
CN1174512A (zh) 蛋氨酸酶在抗蛋氨酸和抗高半胱氨酸的化学治疗中的应用
WO2002044360A2 (en) Modified arginine deiminase
JP2010500963A (ja) 安定化タンパク質
CN101193658B (zh) 聚乙二醇化g-csf多肽及其产生方法
US8759060B2 (en) PEG-modified arginine/lysine oxidoreductase
CN101591649B (zh) 甲氧基聚乙二醇修饰的精氨酸脱亚氨酶及其制备与应用
EA006368B1 (ru) Химически модифицированные конъюгаты прогенипоэтина
CN1161375C (zh) 改善了靶细胞受体结合活性的融合蛋白质
Tsui The development of human recombinant arginase as a novel agent in the treatment of human cancer
JP2011168521A (ja) ＰＥＧ化ｅＭＩＰ及びその製造方法並びにこれを用いた癌治療剤
WO2006015512A1 (en) A modified arginine deiminase
HK1056742B (en) Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates
HK1178936A (en) Engineered enzymes with methionine-gamma-lyase enzymes and pharmacological preparations thereof

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20080201

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080404

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080424

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080424

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20091015

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20101005

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20101228

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110111

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110203

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20110308

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20110318

R150 Certificate of patent or registration of utility model

Ref document number: 4709465

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250